BIOTECH MARKET RESEARCH $CRSP | Ep. 642

CRISPR Therapeutics

CRISPR Therapeutics (CRSP) is approaching a critical juncture with two upcoming Phase 1 data readouts for its in vivo gene editing programs targeting cardiometabolic diseases. Interim data from CTX310, a CRISPR/Cas9-mediated ANGPTL3 knockout therapy, is expected in 1H 2025. Also, CTX320, which targets Lp(a) through LPA gene knockout, is anticipated to report initial clinical data in 2H 2025. These single-dose therapies aim to deliver durable reductions in atherogenic lipoproteins, positioning CRISPR as a disruptive player in cardiovascular medicine. Investors are closely watching for signs of robust target engagement, clean safety, and long-lasting effects - outcomes that could validate CRISPR’s broader ambitions beyond rare diseases. Market sentiment reflects cautious optimism, with volatility likely elevated (+/- 60%) as these high-impact data readouts approach.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

🚨 ALERT: Two Phase 1 data readouts incoming for CRISPR Therapeutics’ cardiometabolic programs – CTX310 (ANGPTL3 knockout) and CTX320 (Lp(a) knockout), both single-dose in vivo gene editing therapies.

📅 DATE: CTX310 & CTX320: 1H 2025

📈 IMPLIED VOLATILITY: +/- 60%

BACKGROUND: